OMLIAGO Trademark

Trademark Overview

On Wednesday, June 8, 2022, a trademark application was filed for OMLIAGO with the United States Patent and Trademark Office. The USPTO has given the OMLIAGO trademark a serial number of 97449122. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, March 13, 2026. This trademark is owned by Genentech, Inc.. The OMLIAGO trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical oncology preparations
omliago

General Information

Serial Number97449122
Word MarkOMLIAGO
Filing DateWednesday, June 8, 2022
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, March 13, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 28, 2023

Trademark Statements

Goods and Servicespharmaceutical oncology preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, June 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenentech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
US
Party NameGenentech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
US

Trademark Events

Event DateEvent Description
Saturday, June 11, 2022NEW APPLICATION ENTERED
Saturday, June 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, January 23, 2023ASSIGNED TO EXAMINER
Thursday, January 26, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, February 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, April 19, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, April 19, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 19, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, April 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, October 11, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 11, 2023SOU EXTENSION 1 FILED
Wednesday, October 11, 2023SOU EXTENSION 1 GRANTED
Friday, October 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 15, 2024SOU TEAS EXTENSION RECEIVED
Monday, April 15, 2024SOU EXTENSION 2 FILED
Monday, April 15, 2024SOU EXTENSION 2 GRANTED
Tuesday, April 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 14, 2024SOU TEAS EXTENSION RECEIVED
Monday, October 14, 2024SOU EXTENSION 3 FILED
Monday, October 14, 2024SOU EXTENSION 3 GRANTED
Monday, October 14, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 16, 2025SOU TEAS EXTENSION RECEIVED
Thursday, April 17, 2025SOU EXTENSION 4 FILED
Thursday, April 17, 2025SOU EXTENSION 4 GRANTED
Thursday, April 17, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 9, 2025SOU TEAS EXTENSION RECEIVED
Thursday, March 12, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 8, 2025SOU EXTENSION 5 FILED
Friday, March 13, 2026SOU EXTENSION 5 GRANTED
Friday, March 13, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

omliago preparations oncology pharmaceutical